- Home
- DYAI vs ACRV Comparison
DYAI vs ACRV Comparison
Compare DYAI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- ACRV
- Stock Information
- Founded
- DYAI 1979
- ACRV 2018
- Country
- DYAI United States
- ACRV United States
- Employees
- DYAI N/A
- ACRV N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- DYAI Health Care
- ACRV Health Care
- Exchange
- DYAI Nasdaq
- ACRV Nasdaq
- Market Cap
- DYAI 31.3M
- ACRV 34.5M
- IPO Year
- DYAI 2004
- ACRV 2022
- Fundamental
- Price
- DYAI $0.97
- ACRV $1.25
- Analyst Decision
- DYAI Strong Buy
- ACRV Buy
- Analyst Count
- DYAI 1
- ACRV 7
- Target Price
- DYAI $6.00
- ACRV $17.60
- AVG Volume (30 Days)
- DYAI 37.8K
- ACRV 750.0K
- Earning Date
- DYAI 05-14-2025
- ACRV 05-14-2025
- Dividend Yield
- DYAI N/A
- ACRV N/A
- EPS Growth
- DYAI N/A
- ACRV N/A
- EPS
- DYAI N/A
- ACRV N/A
- Revenue
- DYAI $3,554,344.00
- ACRV N/A
- Revenue This Year
- DYAI $22.56
- ACRV N/A
- Revenue Next Year
- DYAI $30.95
- ACRV N/A
- P/E Ratio
- DYAI N/A
- ACRV N/A
- Revenue Growth
- DYAI 57.59
- ACRV N/A
- 52 Week Low
- DYAI $0.93
- ACRV $1.05
- 52 Week High
- DYAI $2.67
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- DYAI 36.18
- ACRV 44.21
- Support Level
- DYAI $0.95
- ACRV $1.06
- Resistance Level
- DYAI $1.13
- ACRV $1.19
- Average True Range (ATR)
- DYAI 0.08
- ACRV 0.10
- MACD
- DYAI 0.00
- ACRV 0.07
- Stochastic Oscillator
- DYAI 20.00
- ACRV 78.43
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.